Syngene International Limited — Call Transcript 2022

Jul 18, 2022

==> picture [133 x 33] intentionally omitted <==

Ref: Syn/CS/SE/Reg 30/2022-23/Jul/07

Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC01493 www.syngeneintl.com

July 18, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street,Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra(EAST),Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Subject: Intimation of Conference Call for Analysts and Investors

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, July 21, 2022.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Digitally signed by PRIYADARSHINI MAHAPATRA DN: c=IN, o=Personal, pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9b PRIYADARSHIN 276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef2622 9a00b5f723a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb1208 I MAHAPATRA 536f4f1860285e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA Date: 2022.07.18 15:21:30 +05'30'

________ Priyadarshini Mahapatra Company Secretary & Compliance Officer

INVESTOR CONFERENCE CALL INVITE

Q1 FY 2022-23

==> picture [594 x 151] intentionally omitted <==

Syngene’s Q1 FY2023 Results Conference Call

At 03:00 pm IST on 21[st] July 2022

The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Thursday, 21[st] July at 03.00 pm IST following the announcement of financial results for the quarter ended June 30, 2022.

The call will be initiated with a brief management discussion on the Q1 FY2023 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene’s Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Thursday, 21stJuly 2022
Time:	03:00 pm to 04:00 pm IST
Dial-in Numbers*
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
International Numbers	• USA – 18667462133 (Toll Free) /+13233868721 (Toll) • UK – 08081011573 (Toll Free) /+442034785524 (Toll) • Singapore – 8001012045 (Toll Free) /+6531575746 (Toll) • Hong Kong – 800964448 (Toll Free) /+85230186877 (Toll) • Australia – 1800053698 (Toll Free)
Pre-registration Facility (Diamond_Pass_™link)	Step 1: Pre-register here.You will receive a passcode and a pin for the call on the registered email address. Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call

*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

Syngene International: Putting Science to Work

Page 1

==> picture [594 x 151] intentionally omitted <==

INVESTOR CONFERENCE CALL INVITE Q1 FY 2022-23

Replay Facility Dial in numbers: +91 22 7194 5757 / +91 22 66635757 Playback ID: 53984 The replay facility will be available from 21[st ] July 2022 till 28[th] July 2022 Conference Call Transcript Will be available within 7 working days of the call on the corporate website: https://syngeneintl.com/

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 5200 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com

For further information, please contact:

Krishnan G

Syngene International : +91 8068919807 :Krishnan.G@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forwardlooking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.

Syngene International: Putting Science to Work

Page 2